Rheumatic disorders treatment market seen growing to $68.9B by 2030

The global market for rheumatic disorders treatment is projected to rise from $48.6 billion in 2025 to $52.47 billion in 2026, then reach $68.91 billion by 2030, according to a new industry report. Growth is being driven by higher autoimmune disease prevalence, broader use of biologics and biosimilars, and faster adoption of digital diagnostics and monitoring tools.

Why it matters: - Rheumatic disorders treatment is a growing healthcare market tied to chronic conditions that affect mobility, pain levels and long-term quality of life. - Rising demand for diagnostics, biologics, biosimilars and remote-care tools points to a broader shift in how autoimmune and joint diseases are managed.

What happened: - The Business Research Company released The Rheumatic Disorders Treatment Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - The report values the global rheumatic disorders treatment market at $48.6 billion in 2025. - The market is projected to reach $52.47 billion in 2026, at an 8.0% CAGR. - The report forecasts the market will climb to $68.91 billion by 2030, at a 7.1% CAGR.

The details: - Rheumatic disorders treatment covers therapies for diseases affecting joints, muscles, connective tissues and the immune system. - The report includes rheumatoid arthritis, osteoarthritis, lupus, gout and ankylosing spondylitis. - Treatment goals include reducing pain and inflammation, slowing disease progression, improving mobility and preserving joint function. - Growth factors cited in the report include higher global incidence of autoimmune and rheumatic diseases, wider use of biologic therapies and improved clinical diagnostics. - The report also points to expanded healthcare infrastructure, including specialized rheumatology clinics, and greater awareness of joint health and mobility issues. - Future growth is expected to come from precision medicine, targeted immunotherapies, AI-powered diagnostic and treatment tools, biosimilars, telemedicine, remote monitoring, regenerative therapies and disease-modifying therapies. - Emerging trends include AI-based personalized treatment plans, broader use of biologic and biosimilar drugs, wearable patient-monitoring devices and digital disease-management platforms. - A download link for a free sample of the report is available here: the sample report. - The full report is available here: the full market report.

Between the lines: - The market forecast suggests rheumatic care is moving toward more personalized, tech-enabled and long-duration treatment models. - Greater use of biosimilars could help widen access by lowering treatment costs, while digital monitoring may shift some care outside traditional clinics. - The CDC reported in January 2024 that about 21.3% of U.S. adults in 2023, or around 53.2 million people, had doctor-diagnosed arthritis, up from 21.2% in 2022. - North America held the largest market share in 2025, while Asia-Pacific is expected to grow fastest during the forecast period. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa.

What's next: - The report expects continued investment in AI, telemedicine, wearable monitoring and regenerative medicine to shape product development and care delivery. - Broader adoption of biosimilars and targeted therapies may expand treatment access and support long-term disease control through 2030. - The Business Research Company also highlighted new report features, including market attractiveness scoring, TAM analysis, company scoring matrices, Excel-based forecasting dashboards, hotspots infographics and updated graphics and tables.

The bottom line: - Rheumatic disorders treatment is positioned for steady expansion as autoimmune disease burden grows and care becomes more digital, personalized and biologics-driven.